CRS conducts in-house Bioavailability (BA) and Bioequivalence (BE) studies within its dedicated clinical research unit, providing sponsors with an efficient and controlled setting for comparative pharmacokinetic evaluation. Our infrastructure and operational model are designed to support both regulatory-driven BE programs and exploratory BA assessments with high precision and consistency.

We support a wide range of BA/BE study designs, including single-dose and multiple-dose crossover studies, fasting and fed conditions, and replicate designs where required. Careful attention is given to dosing accuracy, washout periods, and protocol-defined timing to ensure reliable and reproducible pharmacokinetic data. All study activities are performed under medical supervision in accordance with Good Clinical Practice.

CRS manages the complete conduct of in-house BA/BE studies, including volunteer recruitment, screening, dosing, inpatient stays, outpatient visits, and intensive pharmacokinetic sampling. Our unit is experienced in handling dense sampling schedules and strict time-point adherence, which are critical for robust comparative analyses.

Clinical operations are closely coordinated with bioanalytical laboratories, data management, and statistical teams to support accurate data handling and timely analysis. Quality control measures are embedded throughout study conduct to ensure data integrity and regulatory acceptability.

By combining dedicated facilities, experienced operational teams, and integrated clinical services, CRS delivers BA/BE studies that support confident regulatory submissions and informed product development decisions.